Cerebrovascular Diseases

Therapeutic Interventions in

Action on Vascular Risk Factors: Importance of Blood Pressure and Lipid Lowering in Stroke Secondary Prevention

Fuentes B. · Ortega-Casarrubios M.A. · Martínez P. · Díez-Tejedor E.

Author affiliations

Stroke Unit, Department of Neurology, University Hospital La Paz, Universidad Autónoma de Madrid, Madrid, Spain

Keywords: Secondary stroke preventionHypertensionDyslipidemiaAntihypertensive drugsStatins

Related Articles for ""
Cerebrovasc Dis 2007;24:96–106
https://doi.org/10.1159/000107384

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Therapeutic Interventions in

Published online: November 01, 2007
Issue release date: November 2007

Number of Print Pages: 11
Number of Figures: 0
Number of Tables: 2

ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)

For additional information: https://www.karger.com/CED

Abstract

Introduction: Secondary stroke prevention comprises a broad spectrum of therapeutic actions that includes the appropriate management of risk factors and the action on blood pressure and serum lipids that are of great importance to decrease stroke recurrences. Methods: We conducted a review of the published studies analyzing the relevance of the treatment of blood pressure and serum lipids, with special attention to recent findings of clinical trials and current guidelines on stroke secondary prevention. Results: The relationship between blood pressure and stroke has been widely demonstrated; however, the role of serum lipids has been discussed for a long time. Recent results from epidemiological studies and clinical trials have demonstrated its role as modifiable risk factor for stroke. Blood pressure and lipid lowering are associated with significant reductions in recurrent strokes as well as in other vascular events in transient ischemic attack (TIA) or stroke patients. The PROGRESS and MOSES trials suggest that diuretics, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers could confer additional benefits in stroke patients, and the SPARCL study did so for statins. These drugs are not only efficacious in the reduction of stroke recurrences, but also in other cardiovascular events. Conclusions: Blood pressure and serum lipids are two important and modifiable vascular risk factors that should be taken into consideration when planning secondary stroke prevention measures. This approach should include hypotensive drugs (mainly the combination of diuretics and ACE inhibitors) with the objective to maintain normal blood pressure, avoiding levels >130/80 mm Hg in all stroke patients, and statins (atorvastatin 80 mg) in patients with noncardioembolic TIA or stroke.

© 2007 S. Karger AG, Basel



Related Articles:

References

  1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–1913.
    External Resources
  2. Lawes CM, Bennett DA, Feigin VL, Rodgers A: Blood pressure and stroke: an overview of published reviews. Stroke 2004;35:776–785.
    External Resources
  3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–1252.
    External Resources
  4. Lawes CM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A: Blood pressure and the global burden of disease 2000. II. Estimates of attributable burden. J Hypertens 2006;24:423–430.
    External Resources
  5. Kjeldsen SE, Julius S, Hedner T, Hansson L: Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials. Blood Press 2001;10:190–192.
  6. Carter A: Hypotensive therapy in stroke survivors. Lancet 1970;i:485–489.
    External Resources
  7. Hypertension-Stroke Cooperative Group: Effect of antihypertensive treatment on stroke recurrence. JAMA 1974;229:409–418.
    External Resources
  8. PATS Collaborating Group: Post-stroke antihypertensive treatment study: a preliminary result. PATS Collaborating Group. Chin Med J (Engl) 1995;108:710–717.
    External Resources
  9. The Dutch TIA Trial Study Group: Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke 1993;24:543–548.
    External Resources
  10. Eriksson S, Olofsson B, Wester PO: Atenolol in secondary prevention after stroke. Cerebrovasc Dis 1995;5:21–25.
    External Resources
  11. Lindholm LH, Carlberg B, Samuelsson O: Should β-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545–1553.
    External Resources
  12. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145–153.
    External Resources
  13. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, et al: Use of ramipril in preventing stroke: double-blind randomised trial. BMJ 2002;324:699–702.
    External Resources
  14. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033–1041.
    External Resources
  15. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al: Morbidity and Mortality after Stroke – Eprosartan Compared with Nitrendipine for Secondary Prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218–1226.
    External Resources
  16. Sleight P: The ONTARGET/TRANSCEND trial programme: baseline data. Acta Diabetol 2005;42(suppl 1):S50–S56.
    External Resources
  17. Diener HC, Sacco R, Yusuf S, Steering Committee, PRoFESS Study Group: Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis 2007;23:368–380.
    External Resources
  18. Rashid P, Leonardi-Bee J, Bath P: Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003;34:2741–2748.
    External Resources
  19. Zhang H, Thijs L, Staessen JA: Blood pressure lowering for primary and secondary prevention of stroke. Hypertension 2006;48:187–195.
    External Resources
  20. Messerli FH, Grossman E, Lever AF: Do thiazide diuretics confer specific protection against strokes? Arch Intern Med 2003;163:2557–2560.
    External Resources
  21. Zhou J, Pavel J, Macova M, Yu ZX, Imboden H, Ge L, et al: AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats. Stroke 2006;37:1271–1276.
    External Resources
  22. Takemori K, Ishida H, Ito H: Continuous inhibition of the renin-angiotensin system and protection from hypertensive end-organ damage by brief treatment with angiotensin II type 1 receptor blocker in stroke-prone spontaneously hypertensive rats. Life Sci 2005;77:2233–2245.
    External Resources
  23. Sironi L, Gelosa P, Guerrini U, Banfi C, Crippa V, Brioschi M, et al: Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall. J Pharmacol Exp Ther 2004;311:989–995.
    External Resources
  24. Ando H, Jezova M, Zhou J, Saavedra JM: Angiotensin II AT1 receptor blockade decreases brain artery inflammation in a stress-prone rat strain. Ann NY Acad Sci 2004;1018:345–350.
    External Resources
  25. Ito T, Nishimura Y, Saavedra J: Pre-treatment with candesartan protects from cerebral ischaemia. J Renin Angiotensin Aldosterone Syst 2001;2:174–179.
    External Resources
  26. Ito T, Yamakawa H, Bregonzio C, Terron JA, Falcon-Neri A, Saavedra JM: Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke 2002;33:2297–2303.
    External Resources
  27. Fornes P, Richer C, Vacher E, Bruneval P, Giudicelli JF: Losartan’s protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal. J Cardiovasc Pharmacol 1993;22:305–313.
    External Resources
  28. Selim M, Savitz S, Linfante I, Caplan L, Schlaug G: Effect of pre-stroke use of ACE inhibitors on ischemic stroke severity. BMC Neurol 2005;5:10.
    External Resources
  29. Ortega Casarrubios MA, Fuentes B, San José MJ, Aguilar-Amat MJ, Ybot I, Martínez P, et al: Previous treatment with angiotensin II receptor blockers could play a possible protector effect in acute stroke. Cerebrovasc Dis 2007;23(suppl 2):107.
  30. Richer C, Fornes P, Vacher E, Bruneval P, Giudicelli JF: Trandolapril’s protective effects in stroke-prone spontaneously hypertensive rats persist long after treatment withdrawal. Am J Cardiol 1994;73:26C–35C.
    External Resources
  31. Vacher E, Fornes P, Domergue V, Richer C, Bruneval P, Giudicelli JF: Quinapril prevents stroke both during and after the treatment period in stroke-prone spontaneously hypertensive rats. Am J Hypertens 1993;6:951–959.
    External Resources
  32. Chitravas N, Dewey HM, Nicol MB, Harding DL, Pearce DC, Thrift AG: Is prestroke use of angiotensin-converting enzyme inhibitors associated with better outcome? Neurology 2007;68:1687–1693.
    External Resources
  33. Ovbiagele B, Kidwell CS, Starkman S, Selco SL, Rajajee V, Razinia T, et al: Angiotensin II type 2 receptor activity and ischemic stroke severity. Neurology 2005;65:851–854.
    External Resources
  34. Fournier A, Achard JM, Boutitie F, Mazouz H, Mansour J, Oprisiu R, et al: Is the angiotensin II type 2 receptor cerebroprotective? Curr Hypertens Rep 2004;6:182–189.
    External Resources
  35. Unger T: Blood pressure lowering and renin-angiotensin system blockade. J Hypertens Suppl 2003;21:S3–S7.
    External Resources
  36. Gorelick PB: New horizons for stroke prevention: PROGRESS and HOPE. Lancet Neurol 2002;1:149–156.
    External Resources
  37. Schmieder RE: Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hypertens 2005;18:720–730.
    External Resources
  38. Schulz R, Heusch G: Angiotensin II type 1 receptors in cerebral ischaemia-reperfusion: initiation of inflammation. J Hypertens Suppl 2006;24:S123–S129.
    External Resources
  39. Thöne-Reineke C, Steckelings UM, Unger T: Angiotensin receptor blockers and cerebral protection in stroke. J Hypertens Suppl 2006;24:S115–S121.
    External Resources
  40. Perry HM Jr, Davis BR, Price TR, Applegate WB, Fields WS, Guralnik JM, et al: Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 2000;284:465–471.
    External Resources
  41. Chapman N, Huxley R, Anderson C, Bousser MG, Chalmers J, Colman S, et al: Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke 2004;35:116–121.
    External Resources
  42. Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S, et al: Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005;112:1339–1346.
    External Resources
  43. PROGRESS Collaborative Group: Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 2003;24:475–484.
    External Resources
  44. Elias MF, Wolf PA, D’Agostino RB, Cobb J, White LR: Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol 1993;138:353–364.
    External Resources
  45. Kilander L, Nyman H, Boberg M, Hansson L, Lithell H: Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension 1998;31:780–786.
    External Resources
  46. Knopman D, Boland LL, Mosley T, Howard G, Liao D, Szklo M, et al: Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 2001;56:42–48.
    External Resources
  47. de la Torre JC: Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002;33:1152–1162.
    External Resources
  48. Peila R, White LR, Masaki K, Petrovitch H, Launer LJ: Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke 2006;37:1165–1170.
    External Resources
  49. Amenta F, Mignini F, Rabbia F, Tomassoni D, Veglio F: Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension: analysis of published clinical data. J Neurol Sci 2002;203–204:147–151.
  50. Hanon O, Pequignot R, Seux ML, Lenoir H, Bune A, Rigaud AS, et al: Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints. J Hypertens 2006;24:2101–2107.
    External Resources
  51. Prince MJ, Bird AS, Blizard RA, Mann AH: Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council’s trial of hypertension in older adults. BMJ 1996;312:801–805.
    External Resources
  52. Kehoe PG, Wilcock GK: Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer’s disease? Lancet Neurol 2007;6:373–378.
    External Resources
  53. McGuinness B, Todd S, Passmore P, Bullock R: The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst Rev 2006;2:CD004034.
  54. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al: Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998;352:1347–1351.
    External Resources
  55. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al: The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002;162:2046–2052.
    External Resources
  56. Sever P: The SCOPE trial. Study on Cognition and Prognosis in the Elderly. J Renin Angiotensin Aldosterone Syst 2002;3:61–62.
    External Resources
  57. Skoog I, Lithell H, Hansson L, Elmfeldt D, Hofman A, Olofsson B, et al: Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on Cognition and Prognosis in the Elderly (SCOPE). Am J Hypertens 2005;18:1052–1059.
    External Resources
  58. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J, PROGRESS Collaborative Group: Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003;163:1069–1075.
    External Resources
  59. Pathak A, Hanon O, Negre-Pages L, Sevenier F, on behalf of the OSCAR investigators: Rationale, design and methods of the OSCAR study: observational study on cognitive function and systolic blood pressure reduction in hypertensive patients. Fundam Clin Pharmacol 2007;21:199–205.
    External Resources
  60. Peters R, Beckett N, Nunes M, Fletcher A, Forette F, Bulpitt C: A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging 2006;23:83–92.
    External Resources
  61. Fuentes B, Díez-Tejedor E, Gil-Nuñez A, Gil-Peralta A, Matías-Guiu J: Guía para el tratamiento preventivo de la isquemia cerebral; in Díez-Tejedor E (ed): Guía para el diagnóstico y tratamiento del ictus. Barcelona, Prous Science, 2006, pp 133–183.
  62. Leys D, Kwiecinski H, Bogousslavsky J, Bath P, Brainin M, Diener HC, et al: Prevention – European Stroke Initiative. Cerebrovasc Dis 2004;17(suppl 2):15–29.
    External Resources
  63. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al: Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Stroke 2006;37:577–617.
    External Resources
  64. Prospective studies collaboration: Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995;346:1647–1653.
    External Resources
  65. Paciaroni M, Hennerici M, Agnelli G, Bogousslavsky J: Statins and stroke prevention. Cerebrovasc Dis 2007;24:170–182.
    External Resources
  66. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD: Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989;320:904–910.
    External Resources
  67. Konishi M, Iso H, Komachi Y, Iida M, Shimamoto T, Jacobs DR Jr, et al: Associations of serum total cholesterol, different types of stroke, and stenosis distribution of cerebral arteries. The Akita Pathology Study. Stroke 1993;24:954–964.
    External Resources
  68. Vivancos-Mora J, Gil-Nunez AC: Lipids and stroke: the opportunity of lipid-lowering treatment. Cerebrovasc Dis 2005;20(suppl 2):53–67.
    External Resources
  69. Ebrahim S, Sung J, Song YM, Ferrer RL, Lawlor DA, Davey Smith G: Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study. BMJ 2006;333:22.
    External Resources
  70. Laloux P, Galanti L, Jamart J: Lipids in ischemic stroke subtypes. Acta Neurol Belg 2004;104:13–19.
    External Resources
  71. Amarenco P, Labreuche J, Elbaz A, Touboul PJ, Driss F, Jaillard A, et al: Blood lipids in brain infarction subtypes. Cerebrovasc Dis 2006;22:101–108.
    External Resources
  72. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–1389.
    External Resources
  73. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22.
    External Resources
  74. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001–1009.
    External Resources
  75. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. N Engl J Med 1998;339:1349–1357.
    External Resources
  76. Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, et al: Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998;129:681–689.
    External Resources
  77. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, et al: Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The Greek Atorvastatin and Coronary-Heart-Disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220–228.
    External Resources
  78. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425–1435.
    External Resources
  79. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149–1158.
    External Resources
  80. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685–696.
    External Resources
  81. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG: Stroke, statins, and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997;28:946–950.
    External Resources
  82. Hebert PR, Gaziano JM, Chan KS, Hennekens CH: Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 1997;278:313–321.
    External Resources
  83. Bucher HC, Griffith LE, Guyatt GH: Effect of HMG CoA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials. Ann Intern Med 1998;128:89–95.
    External Resources
  84. Ross SD, Allen IE, Connelly JE, Korenblat BM, Smith ME, Bishop D, et al: Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 1999;159:1793–1802.
    External Resources
  85. Di Mascio R, Marchioli R, Tognoni G: Cholesterol reduction and stroke occurrence: an overview of randomized clinical trials. Cerebrovasc Dis 2000;10:85–92.
    External Resources
  86. Byington RP, Davis BR, Plehn JF, White HD, Baker J, Cobbe SM, et al: Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation 2001;103:387–392.
    External Resources
  87. Amarenco P, Labreuche J, Lavallee P, Touboul PJ: Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004;35:2902–2909.
    External Resources
  88. Crouse JR 3rd, Byington RP, Furberg CD: HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atherosclerosis 1998;138:11–24.
    External Resources
  89. Leppala JM, Virtamo J, Fogelholm R, Albanes D, Heinonen OP: Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants. Stroke 1999;30:2535–2540.
    External Resources
  90. Okumura K, Iseki K, Wakugami K, Kimura Y, Muratani H, Ikemiya Y, et al: Low serum cholesterol as a risk factor for hemorrhagic stroke in men: a community-based mass screening in Okinawa, Japan. Jpn Circ J 1999;63:53–58.
    External Resources
  91. Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT Jr, Psaty BM: Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 2004;63:1868–1875.
    External Resources
  92. Cui R, Iso H, Toyoshima H, Date C, Yamamoto A, Kikuchi S, et al: Serum total cholesterol levels and risk of mortality from stroke and coronary heart disease in Japanese: the JACC study. Atherosclerosis, E-pub ahead of print September 11, 2006.
  93. Denti L, Cecchetti A, Annoni V, Merli MF, Ablondi F, Valenti G: The role of lipid profile in determining the risk of ischemic stroke in the elderly: a case-control study. Arch Gerontol Geriatr 2003;37:51–62.
    External Resources
  94. Schulz UG, Rothwell PM: Differences in vascular risk factors between etiological subtypes of ischemic stroke: importance of population-based studies. Stroke 2003;34:2050–2059.
    External Resources
  95. Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative Group: Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757–767.
    External Resources
  96. Coull BM: Statin therapy after acute ischemic stroke in the heart protection study: is the role in recurrent stroke prevention now defined? Stroke 2004;35:2233–2234.
    External Resources
  97. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549–559.
    External Resources
  98. Heart Protection Study Collaborative Group: Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007;45:645–654, discussion 653–654.
    External Resources
  99. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–1278.
    External Resources
  100. Wiviott SD, Cannon CP: The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Curr Opin Lipidol 2006;17:626–630.
    External Resources
  101. Goldstein LB, Amarenco P, Szarek M, Callahan A 3rd, Hennerici M, Sillesen H, et al: Secondary analysis of hemorrhagic stroke in the Stroke Prevention by Agressive Reduction in Cholesterol Levels (SPARCL) study. Stroke 2007;38:457.
  102. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712–1719.
    External Resources
  103. Calabro P, Yeh ET: The pleiotropic effects of statins. Curr Opin Cardiol 2005;20:541–546.
    External Resources
  104. Amarenco P, Moskowitz MA: The dynamics of statins: from event prevention to neuroprotection. Stroke 2006;37:294–296.
    External Resources
  105. Ovbiagele B, Saver JL, Starkman S, Kim D, Ali LK, Jahan R, et al: Statin enhancement of collateralization in acute stroke. Neurology 2007;68:2129–2131.
    External Resources
  106. Aslanyan S, Weir CJ, McInnes GT, Reid JL, Walters MR, Lees KR: Statin administration prior to ischaemic stroke onset and survival: exploratory evidence from matched treatment-control study. Eur J Neurol 2005;12:493–498.
    External Resources
  107. Marti-Fabregas J, Gomis M, Arboix A, Aleu A, Pagonabarraga J, Belvis R, et al: Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 2004;35:1117–1121.
    External Resources
  108. Moonis M, Kane K, Schwiderski U, Sandage BW, Fisher M: HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke 2005;36:1298–1300.
    External Resources
  109. Martínez-Sánchez P, Rivera-Ordóñez C, Fuentes B, Ortega Casarrubios MA, Aguilar MJ, Abenza MJ, et al: Treatment with statins is a factor of better outcome after an ischemic stroke, especially in the lacunar subtype. Stroke 2007;38:478.
  110. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–3421.
    External Resources
  111. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–239.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Therapeutic Interventions in

Published online: November 01, 2007
Issue release date: November 2007

Number of Print Pages: 11
Number of Figures: 0
Number of Tables: 2

ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)

For additional information: https://www.karger.com/CED

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2007, Vol.24, Suppl. 1

November 2007

Article

Recommend This
TOP